Sadarangani et al. [5] describe the positive response of endometrium and endometrial cancer cell lines to TRAIL, and Llobelt et al. [30] demonstrate that endometrial cancer cells, primarily insensitive to TRAIL, can be sensitized to the ligand after administration of chemotherapeutics. This evidence concerns the gene TNFSF10 and endometrial cancer.